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• Epilepsy is the most frequently diagnosed chronic
neurological condition in children and affects
between 0.5% and 1% of children1
• Behavioral disorders are disproportionately high in
children with epilepsy and include increased
anxiety, depression, irritability, hyperactivity, and
aggression.2 Psychiatric disorders have been
identified in up to 34% of children with seizures,
compared to 6.6% in the general population.2
• Seizures are traditionally treated with antiepileptic
drugs (AEDs). First-line agents most commonly
used for generalized tonic-clonic seizures include
valproic acid, lamotrigine, and topiramate.3
• Common adverse effects associated with these
drugs are slowed psychomotor speed, poorer
attention, and mild memory impairment.4
• In recent years, marijuana, and more specifically
the compound CBD, has emerged as a potential
treatment for intractable epilepsy in children
This study posed the following question:
• In pediatric patients with drug-resistant epilepsy,
is cannabidiol (CBD) more effective in reducing
seizure activity than traditional anti-epileptic
drugs (AEDs) alone?
A systematic review was utilized to produce this
evidence-based review article. Literature searches
were performed using the PubMed database,
Arcadia’s Landman Library EBSCO database, and
Google scholar. Key words such as “refractory
epilepsy”, “children”, “CBD”, and “cannabis” were
included in the search terms. Exclusion criteria were
non-human subjects and meta-analysis or
systematic reviews. Seven of the most relevant
articles were selected for critical analysis.
Conclusions
• The seven studies chosen for this evidence-based
review article demonstrate promising results for
the use of cannabidiol oil in treating intractable
pediatric epilepsy
• Future research should focus on randomized
control trials with rigorous study designs
• Due to the lack of availability and access, no
change in standard treatment practices can be
recommended at this time, but these studies
demonstrate positive findings and indicate that
CBD can reduce seizure frequency in some
pediatric patients
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• There was a statistically significant change in
participant seizure frequency in five of the seven
studies included, and CBD was not found to cause
serious or life-threatening adverse effects
• A major issue with this systematic review is that only
one of the relevant studies is an RCT. This makes it
difficult to assess the efficacy of CBD, as only RCTs
can adequately control for bias and produce the
strongest evidence
• Selection bias, small sample sizes, and lack of
comprehensive outcome measurements are the
issues most affecting the validity and generalizability
of these studies





Mitelpunkt et al 
(2019) Prospective Cohort 16 2-15 12 weeks PTL-101
CGI-I, CGI-S, seizure 
frequency
Devinsky et al 
(2017) RCT 120 2-18 14 weeks GW Pharmaceuticals
CGI-C, CGI-S, QOLCE, 
seizure frequency
Tzadok et al (2016) Retrospective Cohort 74 1-18 3-12 months 20:1 CBD: THC Seizure frequency
Hausman-Kedem et 




Cohort 70 5-23 8-12 months Bionorica Seizure frequency
Porcari et al (2018) Retrospective Cohort 108 1-18 12-36 months
Artisanal 
preparations Seizure frequency
Rosenberg et al 
(2017) Prospective Cohort 60 3-27 12 weeks GW Pharmaceuticals
QOLCE, seizure 
frequency
Key: RCT = Randomized Control Trial; CGI-I = Caregiver Global Impression of Improvement; CGI-S = Caregiver Global Impression of Seizure Severity; 
CGI-C = Caregiver Global Impression of Change; QOLCE = Quality of Life in Childhood Epilepsy
There is hopeful evidence that CBD oil has the potential to increase quality of life and decrease seizure activity in
this specific population. One study, Tzadok et al., demonstrated a reduction in seizure activity in 89% of the
participants (2016). In a separate study, nineteen patients (41%) partially or completely tapered 1–3 AEDs during
the follow-up period due to their improvement in seizure activity (Hausman-Kedem et al., 2018). The results of
Mitelpunkt et al. were particularly promising: 56% of patients reported a ≥50% reduction in their seizures and
two patients became fully seizure-free. At the end of the study, 73% of caregivers reported an improved/very
much improved condition, and 82% reported reduced/very much reduced seizure severity (2019).
